Vigil Neuroscience (NASDAQ:VIGL) and TC Biopharm (NASDAQ:TCBP) Head-To-Head Analysis

TC Biopharm (NASDAQ:TCBPGet Free Report) and Vigil Neuroscience (NASDAQ:VIGLGet Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Earnings & Valuation

This table compares TC Biopharm and Vigil Neuroscience’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TC Biopharm $2.86 million 0.25 -$1.72 million N/A N/A
Vigil Neuroscience N/A N/A -$68.31 million ($2.04) -1.59

TC Biopharm has higher revenue and earnings than Vigil Neuroscience.

Institutional & Insider Ownership

74.9% of TC Biopharm shares are held by institutional investors. Comparatively, 71.8% of Vigil Neuroscience shares are held by institutional investors. 0.1% of TC Biopharm shares are held by insiders. Comparatively, 33.5% of Vigil Neuroscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for TC Biopharm and Vigil Neuroscience, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TC Biopharm 0 0 0 0 N/A
Vigil Neuroscience 1 0 4 0 2.60

TC Biopharm currently has a consensus price target of $1,400.00, suggesting a potential upside of 131,975.47%. Vigil Neuroscience has a consensus price target of $17.40, suggesting a potential upside of 437.04%. Given TC Biopharm’s higher possible upside, research analysts clearly believe TC Biopharm is more favorable than Vigil Neuroscience.

Risk & Volatility

TC Biopharm has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500.

Profitability

This table compares TC Biopharm and Vigil Neuroscience’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TC Biopharm N/A N/A N/A
Vigil Neuroscience N/A -48.56% -43.40%

Summary

TC Biopharm beats Vigil Neuroscience on 6 of the 9 factors compared between the two stocks.

About TC Biopharm

(Get Free Report)

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

About Vigil Neuroscience

(Get Free Report)

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also conducting IND-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.